Compare ENTG & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTG | SNN |
|---|---|---|
| Founded | 1966 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | 16988 |
| Industry | Plastic Products | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 14.3B |
| IPO Year | 2000 | N/A |
| Metric | ENTG | SNN |
|---|---|---|
| Price | $147.88 | $34.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 2 |
| Target Price | ★ $127.80 | $36.25 |
| AVG Volume (30 Days) | ★ 2.0M | 736.5K |
| Earning Date | 04-30-2026 | 03-16-2026 |
| Dividend Yield | 0.27% | ★ 2.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $3,196,600,000.00 | N/A |
| Revenue This Year | $9.27 | $8.58 |
| Revenue Next Year | $9.50 | $5.60 |
| P/E Ratio | $94.08 | ★ $64.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $66.32 | $26.02 |
| 52 Week High | $146.46 | $38.79 |
| Indicator | ENTG | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 72.35 | 57.17 |
| Support Level | $107.76 | $32.03 |
| Resistance Level | N/A | $37.23 |
| Average True Range (ATR) | 4.84 | 0.57 |
| MACD | 2.72 | 0.28 |
| Stochastic Oscillator | 98.67 | 83.48 |
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.